Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 228,908,174 papers from all fields of science
Search
Sign In
Create Free Account
Multiple Sclerosis, Secondary Progressive
Known as:
Secondary Progressive Multiple Sclerosis
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Multiple Sclerosis, Chronic Progressive
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
A Novel Functional Composite Endpoint to Characterize Disease Progression in Patients with Secondary Progressive Multiple Sclerosis (S12.006)
L. Kappos
,
P. Vermersch
,
+12 authors
R. Fox
Neurology
2019
Corpus ID: 196563014
Objective: To evaluate a novel functional composite endpoint (CEP) based on disability progression and cognitive processing speed…
Expand
2017
2017
Time Perspective in Multiple Sclerosis Patients: Looking for Clinical Targets for Psychological Interventions
E. Nikolaev
,
N. Vasil’eva
European psychiatry
2017
Corpus ID: 80280941
2014
2014
Detecting cognitive dysfunction in a busy multiple sclerosis clinical setting: a computer generated approach
H. Lapshin
,
H. Lapshin
,
B. Audet
,
Anthony Feinstein
,
Anthony Feinstein
European Journal of Neurology
2014
Corpus ID: 22255205
This study aims to explore the effectiveness of a brief, computerized battery of tests in detecting cognitive differences between…
Expand
2012
2012
Therapy-related acute leukemia in two patients with multiple sclerosis treated with Mitoxantrone.
N. Čolović
,
N. Suvajdzic
,
+5 authors
D. Tomin
Biomedicine & pharmacotherapy = Biomedecine…
2012
Corpus ID: 29623801
2010
2010
F-Wave Characteristics as Surrogate Markers of Spasticity in Patients With Secondary Progressive Multiple Sclerosis
A. Argyriou
,
P. Karanasios
,
A. Makridou
,
N. Makris
Journal of clinical neurophysiology
2010
Corpus ID: 44308965
We sought to identify significant ulnar nerve conduction abnormalities and also to detect ulnar F-wave variable changes in…
Expand
2008
2008
Secondary progressive multiple sclerosis - clinical course and potential predictive factors.
A. Pokryszko-Dragan
,
E. Gruszka
,
M. Bilińska
,
Marta Dubik-Jezierzańska
Neurologia i Neurochirurgia Polska
2008
Corpus ID: 5626740
BACKGROUND AND PURPOSE To characterize the course of secondary progressive multiple sclerosis (SPMS), with an attempt to assess…
Expand
2008
2008
[Compromise of the cognitive functions in progressive secondary multiple sclerosis].
M. Andreu-Català
,
A. Pascual-Lozano
,
A. Bueno-Cayo
,
I. Boscá-Blasco
,
F. Coret-Ferrer
,
B. Casanova-Estruch
Revista de neurología (Ed. impresa)
2008
Corpus ID: 1360864
AIM To define the patterns of cognitive impairment in a homogeneous group of secondary progressive multiple sclerosis (SPMS…
Expand
2006
2006
Computerised volumetric analysis of lesions in multiple sclerosis using new semi-automatic segmentation software
P. Dastidar
,
T. Heinonen
,
T. Vahvelainen
,
I. Elovaara
,
H. Eskola
Medical and Biological Engineering and Computing
2006
Corpus ID: 22938044
The paper describes the application of new semi-automatic segmentation software to the task of detection of anatomical structures…
Expand
Highly Cited
2003
Highly Cited
2003
Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
J. Avasarala
,
A. Cross
,
D. Clifford
,
B. Singer
,
B. Siegel
,
E. Abbey
Multiple Sclerosis
2003
Corpus ID: 45256954
Mitoxantrone is a recently appro ved drug for patients with secondary progressive multiple sclerosis (SPMS). However, cardiac…
Expand
2000
2000
Interferon beta-1b and secondary progressive multiple sclerosis: licence extension. Useful, but further assessment required.
Prescrire international
2000
Corpus ID: 6158695
(1) Interferon beta-1b is now licensed to treat patients with secondary progressive multiple sclerosis. (2) The clinical file…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE